Dr. David Baker and His Contributions to the Fight Against SARS-CoV-2
We have been in the midst of a global pandemic for the last year and scientists have been hard at work trying to develop new technologies to combat
coronavirus. Dr. David Baker and researchers at the Institute for Protein Design worked on designing picomolar SARS-CoV-2 miniprotein inhibitors.
Dr. Baker works on understanding protein structure and function through computer programs he has designed. These programs were used in attempts
to synthesize a drug to stop the spike proteins on the surface of coronavirus from infecting the human respiratory system.
Dr. Baker Lab’s Process for Designing Miniproteins to Combat Coronavirus:

Goal: To design highaffinity protein
minibinders to the
coronavirus spike
receptor binding domain
[2].

Moving Towards the Future

Strategy 1: Incorporate an alpha helix
from the human receptor into small
proteins that would interact with the
spike receptor binding domain to
achieve higher affinity. A Rosetta
blueprint builder was used to generate
some miniproteins that incorporated
the human alpha helix [2].

Strategy 2: Design a binder from
scratch. This strategy was
advantageous because it created a
large range of possibilities. This
approach utilized de novo (computer)
design and rotamer interaction field
docking [2].

Dr. Baker and his lab use computer algorithms to design
synthetic proteins that may be beneficial in many different
applications. During the COVID-19 pandemic, he used his
resources to try and find a way to stop coronavirus from infecting people and
reducing symptoms. This particular study shows that the developed computer
programs and models developed can quickly respond to a viral threat [1].
Ultimately, Dr. Baker’s ultimate goal is to be able to generate proteins with
these computer programs within weeks of obtaining the genome of a virus,
which would streamline the workflow of experiments. If Baker’s online
design platforms keep improving, this goal is well within reach.
Benefits for the General Public
In this study, Dr. Baker and his lab “produced the most potent antivirals,

The result of both strategies was a
large quantity of possible
minibinders. They were then tested
to se how well they bind to the spike
receptor binding domain. LCB1 and
LCB3 were the miniproteins that
showed the most neutralizing ability
against coronavirus [1].

Movement
of antivirals
into clinical
testing

including LCB1, which is roughly six times more potent on a per mass basis
than the most effective monoclonal antibodies reported thus far” [3]. The
proteins that were designed also are much cheaper to commercially produce
than antibodies, with great stability and few temperature concerns [1]. These
are extremely valuable characteristics to mass vaccine production, seeing as
many people could be quickly and safely protected from COVID-19.
Dr. Baker has a philosophy that the anyone has the ability to help accelerate
science from their own homes, even people who are not scientists. His labs
are extremely inclusive, and value the work that members of the community
do in the public access computer programs he developed (such as Foldit and
Rosetta@home) [4]. Seeing proteins designed by the public, can help Dr.
Baker and his lab move forward in the development of solutions to issues in
the energy, technology, and medicine sectors.
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